LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One, Inc., the leading provider of clinical interpretation, today announced that CompanionDx, a CLIA certified, high-complexity laboratory specializing in integrated genomic solutions, combining diagnostics such as next-generation sequencing, pharmacogenomics and drug monitoring, signed an agreement with N-of-One for N-of-One to provide clinical interpretation for both CompanionDx’s focused and comprehensive oncology panels. Financial terms of the agreement are not disclosed.
CompanionDx’s next-generation sequencing evaluates the DNA in a patient’s tumor via a small biopsy sample. The DNA is analyzed for key changes or somatic mutations. When combined with the company’s pharmacogenomics testing, which establishes a clear understanding of the patient’s potential for metabolizing a drug based on their possible germline variants, CompanionDx can help increase the efficacy of prescribed therapy—creating a safer, more effective and more personalized approach to cancer treatment.
N-of-One Clinical Interpretation is based on proven, deep oncology domain expertise that is constantly updated by N-of-One’s in-house team of PhDs and oncologists. N-of-One delivers comprehensive scientific and clinical evidence that supports possible therapeutic strategies relevant to each specific patient case, including insights into the implication of each patient’s molecular profile on drug sensitivity, drug resistance and potential combination therapies, and is configured to easily and efficiently integrate into each organization's reporting needs.
“CompanionDx selected N-of-One for their cost-effective and comprehensive clinical and scientific evidence and insights regarding possible therapeutic strategies relevant to each patient,” said Michael Stewart, CEO of CompanionDx. “N-of-One clinical interpretation will help us deliver high-quality results for our focused NGS panels as well as our larger comprehensive panels.”
“N-of-One is very pleased to work with the talented team at CompanionDx,” said Chris Cournoyer, CEO of N-of-One. “We are focused on helping CompanionDx deliver valuable insights and evidence to their customers that fits into their business model for small and large gene panels.”
About CompanionDx
CompanionDx is the integrated genomic diagnostic and decision support company. Headquartered in Houston, CompanionDx is committed to enhancing and extending patients’ lives by providing physicians with the actionable intelligence they need. Only CompanionDx has the integrated genomic solutions, combining diagnostics such as next-generation sequencing, pharmacogenomics and therapeutic drug monitoring. CompanionDx’s certified molecular biologists, pathologists and technologists conduct all tests within two CLIA-certified, high-complexity labs, while continually seeking ways to improve the approach to patient therapy. From tumor diagnosis to treatment, CompanionDx delivers the clinical insight physicians need while continuing to advance the field with data intelligence. For more information about how CompanionDx is redefining the patient journey, visit www.companiondxlab.com.
About N-of-One
N-of-One, the leader in clinical interpretation for oncology, leverages its world-class team of experts coupled with a proprietary delivery platform to deliver molecular decision support solutions and services, such as interpretation, to pathologists and oncologists at the point of care. N-of-One’s team of experts has interpreted thousands of samples for pathologists, oncologists and patients worldwide, through partnerships with leading diagnostic companies and hospital systems. N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.
